Regulatory & Industry
GHK-Cu: 50 Years of Research, None on Injection
GHK-Cu has decades of human trials as a topical serum and none as an injection, NPR reports, with an FDA panel reviewing the injectable in February.
Peptides and Cancer: What Memorial Sloan Kettering Says
Peptides sold online for wellness have not been through clinical trials, and Memorial Sloan Kettering has now told patients why that matters.
GLP-1: WHO Guidelines, 1 Billion People, 3 Industries
GLP-1 now has a WHO guideline, and a Science editorial names the three industries competing around it: pharmaceutical, food and wellness.
Tirzepatide CV Approval: The Overlooked 0.92 Hazard Ratio
Tirzepatide gained an FDA cardiovascular indication on 28 August 2026, from a trial that met non-inferiority and missed superiority at P = 0.09.